Canadian drug development company Deep Genomics has got off a $40 million series B round as it looks to double down on its rare genetic disease and artificial intelligence work

'For the first time in human history, our ability to collect data on our biology has outpaced our ability to interpret and act on it'

A variety of organizations are just starting to explore AI-based approaches to precision medicine. Deep Genomics, a Toronto startup, uses AI to reduce the amount of costly trial and error in drug discovery by analyzing large genomic databases, but its first clinical trial won’t ...

Deep Genomics, founded in 2015, is at the forefront of efforts by big companies, startups and university researchers to transform the economics of drug discovery. The problem is apparent. It typically takes several years and costs billions of dollars for pharmaceutical companies to bring a ...

As any high school biology student knows, genes come in pairs. When Brendan Frey recounts the origins of Deep Genomics - the Toronto AI startup he co-founded - he likewise tells a pair of stories, one intimate and tragic, the other immense and world-changing. The way these ...

In the next 24 months, Mr. Frey said Deep Genomics expects to be able to generate a library of 1,000 oligonucleotide compounds that can be used in different ways, from in-house development of the company’s own drugs to research collaborations and preclinical testing ...

By 2050, many of us will have had our genes sequenced making it far easier to identify and treat genetic disorders, which presently affect some 350m people worldwide. In a different building in Toronto’s Mars Discovery District, another pioneer in the field of artificial ...

The next blockbuster drug could be developed with help from machine learning techniques.

Deep Genomics, a Canadian company that uses machine learning to trace potential genetic causes for disease, announced Tuesday that it’s getting into drug development. It joins a growing list of AI ...